Inhibition of transient receptor potential vanilloid‐1 confers neuroprotection, reduces tumor necrosis factor‐alpha, and increases IL‐10 in a rat stroke model

• Published in: Fundamental & clinical pharmacology Vol. 31; no. 4; pp. 420 - 428
• Main Authors: Hakimizadeh, Elham, Shamsizadeh, Ali, Roohbakhsh, Ali, Arababadi, Mohammad Kazemi, Hajizadeh, Mohammad R., Shariati, Mehdi, Rahmani, Mohammad R., Allahtavakoli, Mohammad
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01-08-2017
• Subjects: Acrylamides - pharmacology; Acrylamides - therapeutic use; Adults; Animals; Body temperature; Brain; Bridged Bicyclo Compounds, Heterocyclic - pharmacology; Bridged Bicyclo Compounds, Heterocyclic - therapeutic use; Capsaicin; Capsaicin receptors; Cerebral blood flow; cerebral ischemia; Cytokines; Disease Models, Animal; Edema; Gene expression; IL‐10; Inflammation; Interleukin 10; Interleukin-10 - blood; Ischemia; Latency; Male; Neurological diseases; Neuroprotection; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; Occlusion; Pharmacology; Rats; Rats, Wistar; Rodents; Stroke; Stroke - blood; Stroke - drug therapy; Temperature effects; Transient receptor potential proteins; transient receptor potential vanilloid‐1; TRPV Cation Channels - antagonists & inhibitors; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumor Necrosis Factor-alpha - blood; Tumor necrosis factor-TNF; Tumor necrosis factor-α; tumor necrosis factor‐alpha; tumor necrosis factor-alpha; transient receptor potential vanilloid-1; cerebral ischemia; neuroprotection; IL-10
• ISSN: 0767-3981; 1472-8206
• DOI: 10.1111/fcp.12279

Stroke is a major cause of mortality and long‐term disability in adults. Transient receptor potential vanilloid‐1 (TRPV1) plays a crucial role in neuroinflammation. In this study, the effects of TRPV1 agonist (capsaicin) and antagonist (AMG9810) on cerebral ischemia were investigated. Forty male Wistar rats were assigned to the following experimental groups: sham, vehicle) ischemic), AMG9810 (selective TRPV1 antagonist, 0.5 mg/kg; 3 h after stroke), and capsaicin (1 mg/kg; 3 h after stroke). Stroke was induced by permanent middle cerebral artery occlusion and neurological deficits were evaluated 1, 3, and 7 days after stroke. Then, infarct volume, brain edema, body temperature, mRNA expression of TRPV1, and serum concentrations of tumor necrosis factor‐alpha (TNF‐α) and IL‐10 were measured. Compared to the vehicle group, AMG9810 significantly decreased the infarct volume (P < 0.01). Latency for the removal of sticky labels from the forepaw and the hanging time were significantly decreased and increased, respectively, following administration of AMG9810 (P < 0.01 and P < 0.001 vs. vehicle) 3 and 7 days after stroke. Compared to the sham group, the mRNA expression of TRPV1 was significantly increased in vehicle group (P < 0.01). Administration of AMG9810 significantly increased the anti‐inflammatory cytokine IL‐10 and decreased the inflammatory cytokine TNF‐α (P < 0.05). Moreover, our results indicate that AMG9810 might a promising candidate for the hypothermic treatment of stroke. The findings also suggest a key role for AMG9810 in reducing inflammation after stroke and imply that TRPV1 could be a potential target for the treatment of ischemic stroke.